Erste Asset Management GmbH Lowers Stake in Krystal Biotech, Inc. $KRYS

Erste Asset Management GmbH reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 68.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,700 shares of the company’s stock after selling 12,500 shares during the quarter. Erste Asset Management GmbH’s holdings in Krystal Biotech were worth $1,446,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Public Sector Pension Investment Board grew its holdings in Krystal Biotech by 15.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company’s stock valued at $17,729,000 after buying an additional 13,743 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Krystal Biotech by 469.9% in the fourth quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock worth $4,662,000 after buying an additional 15,591 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Krystal Biotech by 63.9% during the third quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock worth $26,356,000 after acquiring an additional 58,203 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of Krystal Biotech during the third quarter worth $1,450,000. Finally, Handelsbanken Fonder AB grew its stake in Krystal Biotech by 58.4% during the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after acquiring an additional 39,000 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on KRYS shares. HC Wainwright reiterated a “buy” rating and issued a $310.00 price target on shares of Krystal Biotech in a report on Monday, June 1st. Chardan Capital increased their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Wall Street Zen raised Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Guggenheim boosted their target price on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Stock Up 0.9%

KRYS stock opened at $312.41 on Thursday. Krystal Biotech, Inc. has a 52 week low of $127.99 and a 52 week high of $320.32. The firm has a market capitalization of $9.21 billion, a P/E ratio of 41.77 and a beta of 0.53. The company has a fifty day simple moving average of $285.99 and a two-hundred day simple moving average of $266.77.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, analysts anticipate that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.